Elucidating the Dynamics of Biodegradation and Biosynthesis of Magnetic Nanoparticles in Human Stem Cells.

Iron oxide nanoparticles, due to their magnetic properties, are versatile tools for biomedical applications serving both diagnostic and therapeutic roles. Their performance is intricately intertwined with their fate in the demanding biological environment. Once inside cells, these nanoparticles can be degraded, implying a loss of magnetic efficacy, but also transformed into neo-synthesized magnetic nanoparticles, potentially restoring functionality.

REVIEW: "ISCHEMIC STROKE: From Fibrinolysis to Functional Recovery" Nanomedicine: emerging approaches to treat ischemic stroke.

Stroke is responsible for 11% of all deaths worldwide, the majority of which are caused by ischemic strokes, thus making the need to urgently find safe and effective therapies. Today, these can be cured either by mechanical thrombectomy when the thrombus is accessible, or by intravenous injection of fibrinolytics. However, the latter present several limitations, such as potential severe side effects, few eligible patients and low rate of partial and full recovery.

The Prognosis of Glutamic Acid Decarboxylase Antibodies in Women With Hyperglycemia in Pregnancy.

Context: We recently reported that the presence of glutamic acid decarboxylase antibodies (GADA) was not associated with large-for-gestational-age infants in women with hyperglycemia in pregnancy (HIP).

Objective: We explored the association between the presence of GADA and other HIP-related adverse pregnancy outcomes.

Methods: This observational prospective study, conducted at a university hospital in a suburb of Paris, France, included 1182 consecutive women with HIP measured for GADA at HIP care initiation between 2012 and 2017.

Photothermia at the nanoscale induces ferroptosis via nanoparticle degradation.

The Fe(II)-induced ferroptotic cell death pathway is an asset in cancer therapy, yet it calls into question the biocompatibility of magnetic nanoparticles. In the latter, Fe(II) is sequestered within the crystal structure and is released only upon nanoparticle degradation, a transition that is not well understood. Here, we dissect the chemical environment necessary for nanoparticle degradation and subsequent Fe(II) release.